WuXi Biologics bags service agreement with BioNTech

11 January 2024
wuxi_large_new

China-based contract research, development and manufacturing organization (CRDMO) WuXi Biologics (2269: HK) saw its shares jump nearly 9% to HK$30.45 by close of trading today, after it announced a new collaboration.

WuXi has signed a research service agreement with German biotech BioNTech (Nasdaq: BNTX), which is pioneering novel mRNA therapies for cancer and other serious diseases, and, in partnership with Pfizer (NYSE: PFE), developed the most successful COVID-10 vaccine Comirnaty).

Under the terms of the agreement, WuXi leverages its proprietary antibody discovery technology platforms to discover two undisclosed targets of pre-clinical investigational monoclonal antibodies for BioNTech to develop next-generation therapeutic product candidates.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology